TLDR
- UnitedHealth stock fell as much as 4.7% Tuesday, hitting a low of $389.50.
- Humana and CVS also fell, pointing to a sector-wide move.
- The low landed just under the 50-day average of $391.36.
- Wells Fargo cut its target to $487, while JPMorgan raised its own to $524.
- The company beat Q3 estimates and set a 2026 earnings floor of $20.50.
UnitedHealth (UNH) stock fell as much as 4.7% in morning trading on Tuesday. It touched $389.50 at the low, well under Monday’s close of $412.02.
UnitedHealth Group Incorporated, UNH
Health insurers were weak from the start. UNH was down about 2.8% in premarket trading, along with Humana and CVS.
The dip took the stock right to a familiar line. Its 50-day moving average sits at $391.36, so the session low landed just under it.
Wall Street’s wider mood did not help. The S&P 500 opened down 0.2%, the Dow lost 0.4%, and the Nasdaq slipped 0.2%.
Traders were waiting on Nvidia’s earnings. They were also weighing new U.S. limits on AI chip exports.
What Is Weighing on Managed Care
Medicare Advantage reimbursement and rising medical costs have kept the group under a microscope. Investing.com said that pressure grew on Tuesday.
Wells Fargo trimmed its price target from $526 to $487 on Oct. 27. It kept its overweight rating.
Other analysts have gone the other way. JPMorgan lifted its target from $516 to $524 on Oct. 16.
The Street leans positive overall. Twenty analysts rate the stock a Buy and eight say Hold, with an average target of $463.93.
The Numbers Behind the Stock
UnitedHealth posted third-quarter earnings of $4.69 a share on Oct. 13. That topped the $4.14 estimate.
Revenue came in at $112.72 billion, versus $111.31 billion expected. The company also set its 2026 earnings floor at $20.50 or better.
The stock is still far above its 12-month low of about $256. Its 12-month high is $461.62.
Optum Rx grew operating earnings in the third quarter even with lower prescription volumes. Biosimilar use and cost savings helped.
Buyers have shown up too. Intech Investment Management raised its stake 36.8% in the third quarter, MarketBeat reported, adding 56,872 to reach 211,490 in all.
On Nov. 11, 51 ETFs bought UNH while nine sold. That added up to $86.8 million in net buying.
CEO Patrick Conway sold $455,910 of stock at $390 on Aug. 21. That trade cut his holdings by 7.09%.
The next quarterly dividend is $2.32, payable Dec. 15 to holders of record on Dec. 7. That is a yield of about 2.3%.
One technical read calls UNH a stock in consolidation, with neutral momentum and thin volume. That points to no strong near-term signal from trading activity.





